Background COVID-19 is associated with both venous and arterial thrombotic complications.
While prophylactic anticoagulation is now widely recommended for hospitalized patients …

Background: COVID-19 (coronavirus disease 2019) is associated with heightened risks of
venous and arterial thrombosis and hospitalization due to respiratory failure. To assess …

Background The devastating Coronavirus disease (COVID-19) pandemic is associated with
a high prothrombotic state. It is unclear if the coagulation abnormalities occur because of the …

Background COVID-19 progression is associated with an increased risk of arterial and
venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the …

Background Patients hospitalised with COVID-19 are at risk for thrombotic events after
discharge; the role of extended thromboprophylaxis in this population is unknown. Methods …

Background Coronavirus disease 2019 (COVID-19) increases thrombosis in hospitalized
patients prompting adoption of different thromboprophylaxis strategies. Safety and efficacy of …

Background: Venous Thromboembolism (VTE) is common among patients with severe
Coronavirus Disease 2019 (COVID-19). Anticoagulation in hospitalized COVID-19 patients …

2020; 18: 844–47. 2 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of
adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; …

Thromboembolism is a common and deadly consequence of COVID-19 infection for
hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and …

Introduction Some local protocols suggest using intermediate or therapeutic doses of
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …